In 2023, BMS received a similar approval across the pond. The National Institute for Health and Care Excellence (NICE) ...

The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...

Population-based cohort study identifies better treatment objectives for women with advanced-stage ovarian cancer. Toxicity management and quality of life should be prioritized over treatment to ...

The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell ...

Bin Yu; Jin Zhou; Hongzhou Cai; Ting Xu; Zicheng Xu; Qing Zou; Min Gu ...

Data suggest that neoadjuvant immune checkpoint inhibitor (ICI) therapy improves outcomes in patients with early-stage triple-negative breast cancer, but adjuvant ICI therapy does not.

The approval was based on data from the randomized, double-blind, placebo-controlled, phase 3 CheckMate -77T trial.

The FDA has approved Opdivo (nivolumab) as neoadjuvant and adjuvant treatment for adults with resectable NSCLC.

The Food and Drug Administration has approved Opdivo before and after surgery for some with non-small cell lung cancer.

Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) ...

The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant). 2. Immune-mediated adverse ...